食事の変化が記憶や炎症に関係する脳マーカーに迅速に影響(Study Finds Dietary Changes Quickly Alter Brain Markers Linked to Memory and Inflammation)

ad

2025-09-30 テキサス大学オースチン校(UT Austin)

テキサス大学オースティン校の研究は、脂肪肝疾患(MASLD)患者を対象に、低カロリーまたは低炭水化物食がわずか2週間で脳代謝マーカーを改善することを示した。97%で肝脂肪が減少し、77%でグルタミン酸、70%でミオイノシトールが低下、炎症や記憶障害リスクに関わる脳化学物質が短期間で変化した。これは肝臓と脳の健康が密接に関連していることを裏付け、食事介入が認知機能低下予防にも有効である可能性を示す。研究は今後、大規模臨床試験でライフステージごとの効果を検証する予定であり、世界的に増加が見込まれるMASLDへの早期介入戦略に道を開く。

<関連情報>

低炭水化物・低カロリー食は、代謝機能障害関連脂肪肝疾患(MASLD)患者の肝臓脂肪を減らし、脳内グルタミン酸およびミオイノシトール濃度を低下させる Low carbohydrate and low-calorie diets reduce liver fat and lower brain glutamate and myo-inositol levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Andreana P. Haley,Jack Knight-Scott,Marie Caillaud,Isabelle Gallagher,Jessica Park,Yanrong Li,Tianyu Wang,Hirofumi Tanaka & Jeffrey D. Browning
Metabolic Brain Disease  Published:10 May 2025
DOI:https://doi.org/10.1007/s11011-025-01624-8

食事の変化が記憶や炎症に関係する脳マーカーに迅速に影響(Study Finds Dietary Changes Quickly Alter Brain Markers Linked to Memory and Inflammation)

Abstract

In a longitudinal cohort study with intervention (NCT05216796), we utilized multiorgan imaging to determine if metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with elevated cerebral glutamate and myo-inositol and to determine their sensitivity to dietary intervention. Fifty-five adults with self-reported MASLD or high MASLD risk (3 + metabolic risk factors) received liver and brain magnetic resonance spectroscopy scans pre and post two-week low carbohydrate (≤30 g/d) or low-calorie (women ~ 1200 kcal/d; men ~ 1500 kcal/d) diet, both known for their ability to reduce liver fat. Forty-four adults completed the study (36 female, average age 54 years). Thirty out of 44 met clinical criterion for MASLD based on neuroimaging (≥ 5% hepatic triglycerides). Intervention was associated with significant decreases in liver fat fraction (mean difference = 3.101, 95% CI 2.104–4.099, p < 0.0001), glutamate (mean difference = 0.753, 95% CI 0.274–1.233, p = 0.0032) and myo-inositol (mean difference = 0.478, 95% CI 0.180–0.775, p = 0.0027) in patients with confirmed MASLD. Thus, MASLD may be a source of glutamate neurotoxicity and neuroinflammation and diet is an effective strategy for supporting brain as well as liver health.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました